Evidence map›Paper›PMID 40451999›Full record

SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Efficacy and safety of continuous subcutaneous ND0612 Infusion compared to oral and alternative regimens in managing motor fluctuations in Parkinson's disease: a systematic review and meta-analysis.

Abdallah Abunamoos, Mohammad Moayad Ahmad Alghaniem, Fares A Qtaishat, Yumna Aljazi, Leen Omar Al-Omari, Izere Salomon, Bara M Hammadeh, Khaled Moghib

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Abdallah AbunamoosFaculty of Medicine, University of Jordan, Amman, 11942, Jordan.
Mohammad Moayad Ahmad AlghaniemFaculty of Medicine, University of Jordan, Amman, 11942, Jordan.
Fares A QtaishatFaculty of Medicine, University of Jordan, Amman, 11942, Jordan.
Yumna AljaziFaculty of Medicine, University of Jordan, Amman, 11942, Jordan.
Leen Omar Al-OmariFaculty of Medicine, University of Jordan, Amman, 11942, Jordan.
Izere SalomonUniversity of Rwanda College of Medicine and Health Sciences, Kigali, Rwanda. izesajw73@gmail.com.ORCID http://orcid.org/0000-0003-3067-560X
Bara M HammadehFaculty of Medicine, Balqa' Applied University, Salt, Jordan.
Khaled MoghibFaculty of Medicine, Cairo University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundContinuous subcutaneous infusion of levodopa/carbidopa (ND0612) is a promising alternative to oral therapy for Parkinson's disease. Motor fluctuations and "off time" significantly impact the quality of life in advanced diseases. This meta-analysis evaluates the effectiveness of ND0612 in reducing "off time," improving the overall quality of life, and enhancing sleep quality.

methodA comprehensive search of 549 studies was performed, and five eligible studies (n = 327) were included after intense screening. The ROB2 tool and ROBINS1 were used to assess the quality of the included studies. The outcomes assessed included reductions in "off time" (hours), quality of life (PDQ-39 scores), and sleep quality (PDSS scores). Statistical heterogeneity was assessed using the I

resultsThe meta-analysis showed a significant reduction in OFF time for ND0612 compared to oral regimens, with a standardized mean difference (SMD) of -0.53 (95% CI: -0.76, -0.30), and compared to placebo with an SMD of -0.30 (95% CI: -1.05, 0.44). For improvement in quality of life, a favorable effect of ND0612 was shown compared to oral regimens (SMD = -0.31, 95% CI: -0.54, -0.08) and placebo (SMD = 0.44, 95% CI: 1.19, -0.32). Sleep quality (PDSS scores) demonstrated a slight improvement compared with oral regimens (SMD = -0.21, 95% CI: -0.44, 0.02) and a more significant improvement compared with placebo (SMD = -0.42, 95% CI: -0.87, 0.03). Overall, ND0612 provided consistent benefits in reducing OFF time and enhancing both quality of life and sleep in patients with Parkinson's disease.

conclusionND0612 significantly reduced "off time" and improved quality of life among Parkinson's disease patients experiencing motor fluctuations. However, its effect on sleep quality was inconsistent, with no clear, robust benefit demonstrated. Overall, this analysis supports ND0612 as an effective therapeutic option in patients with advanced Parkinson's disease.

Indexed as

Antiparkinson AgentsCarbidopaLevodopaParkinson DiseaseAdministration, OralDrug CombinationsHumansInfusions, SubcutaneousQuality of LifeAntiparkinson AgentsCarbidopacarbidopa, levodopa drug combinationDrug CombinationsLevodopaInfusionLevodopaMotor fluctuationsND0612Parkinson’s disease

Identifiers

PMID40451999

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.